There are 15 resources available
652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Presenter: Kathryn Arbour
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1016O - Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC
Presenter: Lukas Flatz
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
653O - Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
Presenter: Jie Wang
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA2 - ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA1 - CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
Presenter: Tina Cascone
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA4 - Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
Presenter: Herbert Ho Fung Loong
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA5 - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
Presenter: Nicolas Girard
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
1687O - PRIMCAT: A novel approach to informing health technology assessment decision making in Australia
Presenter: Fanny Franchini
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Presenter: Aaron Lisberg
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
LBA14 - Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
Presenter: Byoung Chul Cho
Session: Presidential 3
Resources:
Abstract
Slides
Webcast